主页 > 医药科学 >

【drug-news】治疗苯丙酮尿症新药二盐酸沙丙蝶呤

LONDON (Reuters) Sept 25 - The European Medicines Agency has backed approval of Kuvan for treating of hyperphenylalaninemia in patients with phenylketonuria, it said on Thursday.

Kuvan was developed by BioMarin Pharmaceutical but was submitted to the EU agency by Germany's Merck KGaA.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

阅读本文的人还阅读：

【drug-news】迈瑞出资二亿

【medical-news】关注世界第

【medical-news】依泽那太加

【medical-news】流感注射可

我的文章（二）：反义药

作者:admin@医学,生命科学    2010-09-27 11:49
医学,生命科学网